Transplantation as salvage therapy for high-risk patients with myeloma in relapse

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 873-878

  Lee, C K ^a   Barlogie, B ^a   Zangari, M ^a   Fassas, A ^a   Anaissie, E ^a   Morris, C ^a   van Rhee, F ^a   Cottler Fox, M ^a   Thertulien, R ^a   Muwalla, F ^a   Mazher, S ^a   Badros, A ^b   Tricot, G ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Refractory myeloma; Salvage transplantation

Indexed keywords

ALBUMIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; M PROTEIN; MELPHALAN; THIOTEPA; VINCRISTINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL STUDY; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HAZARD ASSESSMENT; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYCOSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SALVAGE THERAPY; SIBLING; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GRAFT SURVIVAL; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SEPSIS; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036952887     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703715     Document Type: Article

References (21)

1. Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55-62.
2. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
3. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
4. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97.
6. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
7. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001; 38: 226-230.
8. Fassas A, Tricot G. Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol 2001; 38: 231-242.
9. Tricot G, Jagannath S, Vesole DH et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7-11.
10. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
11. Barlogie B, Zangari M, Spencer T et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38: 250-259.
12. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
13. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
14. Mansi JL, Cunningham D, Viner C et al. Repeat administration of high dose melphalan in relapsed myeloma. Br J Cancer 1993; 68: 983-987.
15. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
16. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
17. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
18. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-225.
19. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
20. Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355-357.
21. Bosi A, Laszlo D, Labopin M et al. Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675-3684.